Program
TAK-003
A development code. Also written as “TDV” and “Tetravalent Dengue Vaccine (TDV)”.
Its studies are mostly in Dengue, led by Takeda.
Furthest: phase 3, since Jan 31, 20186 company-led studies, 3 open or runningNext primary completion: Apr 14, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 63 open or running | phase 3since Jan 31, 2018 | Jan 31, 2018 | Apr 14, 2027phase 3 · NCT06579755 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 31, 2018First study: phase 3 study in DengueFirst studyNCT03423173 · 923 enrolled · United States
- Sep 22, 2023Phase 3 study in Healthy VolunteersNCT06060067 · 480 enrolled · India
- Aug 29, 2024Phase 3 study in DengueNCT06579755 · 800 enrolled · Argentina, Brazil, Singapore and more
- Oct 29, 2024Phase 3 study in DengueNCT06665035 · 212 planned · Colombia, Thailand
- Dec 15, 2024Phase 3 study in DengueNCT06741683 · 187 enrolled · Japan
- Jun 24, 2025Phase 3 study in DengueNCT07047521 · 496 enrolled · Australia
Ahead
- Apr 14, 2027Primary completion: phase 3 study in DengueNCT06579755
- Mar 3, 2030Primary completion: phase 3 study in DengueNCT06665035
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07047521Dengue · Australia | 3 | Active, not recruiting | Jun 29, 2026 | 496 |
| NCT06741683Dengue · Japan | 3 | Completed | Jul 9, 2025 | 187 |
| NCT06665035Dengue · Colombia, Thailand | 3 | Recruiting | Mar 3, 2030 | 212 |
| NCT06579755Dengue · Argentina, Brazil, Singapore and more | 3 | Active, not recruiting | Apr 14, 2027 | 800 |
| NCT06060067Healthy Volunteers · India | 3 | Completed | May 5, 2025 | 480 |
| NCT03423173Dengue · United States | 3 | Completed | Aug 3, 2018 | 923 |
How it is read
Names in the registry
- “TDV”, 4 entries
- “Tetravalent Dengue Vaccine (TDV)”, 1 entry
- “TAK-003”, 1 entry
Codes read as this program: TAK003.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.